Clinical trials · Michigan
Systemic Sclerosis clinical trials in Michigan
We’re tracking 13 recruiting systemic sclerosis studies with a site in Michigan — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Michigan
- NCT07497087RecruitingPhase 3
Study of nerandomilast for people with systemic sclerosis
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
Ann Arbor, MichiganAges 18 years+ - NCT06655155RecruitingPhase 2
Testing efgartigimod for systemic sclerosis
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
Ann Arbor, MichiganAges 18 years+ - NCT06328777RecruitingPhase 1/Phase 2
CABA-201 CAR T Cells For Systemic Sclerosis
This trial tests a new treatment called CABA-201, a type of CAR T cell therapy that targets a protein called CD19 on immune cells. It aims to calm the overactive immune system in people with Systemic Sclerosis and may help stop or slow damage to skin, lungs, and other organs.
Ann Arbor, MichiganAges 18–75 - NCT07047690RecruitingPhase 2
Nemolizumab for adults with scleroderma
This study tests an investigational drug called nemolizumab for adults with systemic sclerosis (scleroderma). It aims to see if the drug can help reduce skin thickening and other symptoms, especially in people with early or moderate disease.
Ann Arbor, MichiganAges 18 years+ - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Ann Arbor, MichiganAges 18 years+ - NCT06470048RecruitingPhase 2
Testing Ianalumab for Diffuse Cutaneous Systemic Sclerosis
This trial tests a new drug called ianalumab for people with diffuse cutaneous systemic sclerosis (a type of scleroderma affecting the skin and internal organs). It aims to see if the drug can help control the disease activity and reduce skin thickening.
Ann Arbor, MichiganAges 18–70 - NCT07402226Recruiting
Diet study for bloating with scleroderma
This study tests whether a special diet can help reduce bloating and stomach discomfort in people with scleroderma (systemic sclerosis). You'll follow a specific meal plan to see if it improves your digestive symptoms.
Ann Arbor, MichiganAges 18 years+ - NCT06675344Recruiting
A device for fatigue, Raynaud's, and quality of life in scleroderma
This trial tests if a device called Apollo can help reduce fatigue and Raynaud's symptoms and improve quality of life in people with scleroderma (systemic sclerosis). You would use the device at home and track your symptoms using a smartphone app.
Ann Arbor, MichiganAges 18 years+ - NCT06733935RecruitingPhase 1/Phase 2
Study of NKX019 for immune diseases
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
Ann Arbor, MichiganAges 18–75 - NCT07295847RecruitingPhase 1
Study of AZD0120 for autoimmune diseases
This trial tests if a new medication, AZD0120, is safe for people with autoimmune diseases. It aims to help patients by targeting the immune system.
Ann Arbor, MichiganAges 18–75 - NCT06655896RecruitingPhase 2
Rapcabtagene Autoleucel for severe diffuse scleroderma
This trial tests an investigational cell therapy called rapcabtagene autoleucel for people with severe diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The treatment uses your own modified immune cells to potentially calm the disease activity.
Ann Arbor, MichiganAges 18–70 - NCT06646913RecruitingPhase 1
TENS therapy for bloating in scleroderma
This study tests whether a gentle electrical device placed on the skin (TENS) can help reduce bloating and belly discomfort in people with scleroderma. If you have scleroderma and struggle with daily bloating, this trial may offer a non-medication option to try.
Ann Arbor, MichiganAges 18 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Detroit, MichiganAges 18 years+
Systemic Sclerosis trials by city in Michigan
Where these studies are running in Michigan
Institutions with a site for the recruiting systemic sclerosis studies listed above.
- University of Michigan · 7 studies
- Wayne State University/Karmanos Cancer Institute · 2 studies
- Clinical Research Inst of MI
- Clinical Research Institute of Michigan, LLC
- Galderma Investigational Site
- GSK Investigational Site
- Nkarta Investigational Site
- Research Site
What taking part in a systemic sclerosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Systemic Sclerosis trials in other states
Common questions
- Are there systemic sclerosis clinical trials in Michigan?
- Yes. We're currently tracking 13 recruiting systemic sclerosis studies with a site in Michigan, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a systemic sclerosis study in Michigan?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Michigan to take part?
- Not necessarily. These studies have a site in Michigan, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a systemic sclerosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New systemic sclerosis studies open in Michigan regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.